Skip to main content

Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF)

New York Stock Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
44.6Fair

ValueMarkers Composite Index

Top 14%#38,261 of 44,707

DCF data not available

Piotroski
2/9
Weak
Beneish
-0.95
High Risk
Altman
-0.97
Distress
DCF Value
-
N/A
ROIC
7.9%
Low
P/E
0.3
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF) — VMCI valuation read

Composite valuation read on NHKFF: VMCI 45/100 against a Healthcare sector median of 50. The 5-point below-median print is the headline number for Nichi-Iko Pharmaceutical Co., Ltd., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for NHKFF: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on NHKFF: NHKFF trades at 17.0x earnings, 6% below the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of -0.5x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

NHKFF rose 3.3% over the trailing 7 days, with a -3.9% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in NHKFF’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.